ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Iovance Biotherapeutics (IOVA) pipeline and stated timing

Name in SEC filings: IOVANCE BIOTHERAPEUTICS, INC.

Pipeline at a glance

ProgramEventStageStated timingFiling
lifileucel/data readoutStage not statedOctober 23–27, 20268-K ·
lifileucel (AMTAGVI)Topline/data readoutStage not stated268-K ·
lifileucelTopline/data readoutStage not stated278-K ·
lifileucel (AMTAGVI) submission—20278-K ·

Source: ORION, orionbiotechai.com/company/IOVA, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/IOVA

Nearest upcoming stated timing: lifileucel · Topline/data readout · October 23–27, 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

lifileucel

Matched

Topline/data readoutOctober 23–27, 2026

Stage: Not stated

Public float: $534,800,000 · as of · SEC filing

Results will be highlighted in an oral presentation (abstract #3725RO) at the European Society for Medical Oncology (ESMO) meeting in Madrid, Spain, from October 23–27, 2026.

8-K · Filed · Last checked

Source details

Accession 0001104659-26-091619

Alert me · Calendar: same stage and window-end month (2026-10)

lifileucel

Matched

Topline/data readout1H27

Stage: Not stated

Public float: $534,800,000 · as of · SEC filing

Multiple patients have been treated for cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC) with initial data expected in 1H27.

8-K · Filed · Last checked

Source details

Accession 0001104659-26-091619

Alert me · Calendar: same stage and window-end month (2027-06)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
lifileucelClinical results1H27
“Multiple patients have been treated for cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC) with initial data expected in 1H27.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

lifileucelClinical resultsOctober 23–27, 2026
“Results will be highlighted in an oral presentation (abstract #3725RO) at the European Society for Medical Oncology (ESMO) meeting in Madrid, Spain, from October 23–27, 2026.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

lifileucel (AMTAGVI)Clinical results4Q26
“Enrollment is nearly complete in the pivotal cohorts and program updates are expected in 4Q26.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

lifileucel (AMTAGVI)Submission2027
“A supplemental Biologics License Application (sBLA) submission is planned in 2027.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch IOVA

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for IOVA. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See IOVA in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.1H means January–June and 2H means July–December of the stated year, unless the company uses a different fiscal year.A New Drug Application (NDA) or Biologics License Application (BLA) asks the FDA to approve a drug or biologic for sale.